Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin

Clinical Biochemistry

Volumn 45, Issue 10-11, 2012, Pages 780-786

  Delattre, Isabelle K ^a   Musuamba, Flora T ^a   Jacqmin, Philippe ^b   Taccone, Fabio S ^c   Laterre, Pierre François ^d   Verbeeck, Roger K ^a   Jacobs, Frédérique ^c   Wallemacq, Pierre ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Exprimo NV   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

lactams; Population pharmacokinetics; Severe sepsis; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; MEROPENEM; PIPERACILLIN;

ARTICLE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPTIC SHOCK;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORINS; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERACILLIN; SEPSIS; THIENAMYCINS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84862534688     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.030     Document Type: Article

References (39)

1. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
2. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
3. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998, 244:379-386.
4. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535.
5. MacArthur R.D., Miller M., Albertson T., Panacek E., Johnson D., Teoh L., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004, 38:284-288.
6. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007, 45(Suppl. 3):S177-S183.
7. Pea F., Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter?. Crit Care 2009, 13:214.
8. Pea F., Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?. Clin Infect Dis 2006, 42:1764-1771.
9. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002, 19:349-353.
10. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995, 28:143-160.
11. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
12. Mohr J.F., Wanger A., Rex J.H. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004, 48:125-130.
13. Tod M.M., Padoin C., Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?. Clin Pharmacokinet 2001, 40:803-814.
14. Delattre I.K., Musuamba F.T., Verbeeck R.K., Dugernier T., Spapen H., Laterre P.-F., et al. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clin Biochem 2010, 43:589-598.
15. Delattre I.K., Musuamba F.T., Nyberg J., Taccone F.S., Laterre P.-F., Verbeeck R.K., et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 2010, 32:749-756.
16. Roberts J.A., Kirkpatrick C.M.J., Roberts M.S., Dalley A.J., Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35:156-163.
17. Touw D.J., Neef C., Thomson A.H., Vinks A.A. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005, 27:10-17.
18. Roberts J.A., Ulldemolins M., Roberts M.S., McWhinney B., Ungerer J., Paterson D.L., et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339.
19. Lindbom L., Pihlgren P., Jonsson E.N., Jonsson N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005, 79:241-257.
20. Jonsson E.N., Karlsson M.O. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999, 58:51-64.
21. Holford N.H. A size standard for pharmacokinetics. Clin Pharmacokinet 1996, 30:329-332.
22. Anderson B.J., Holford N.H.G. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008, 48:303-332.
23. Allegaert K., Anderson B.J., Cossey V., Holford N.H.G. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006, 61:39-48.
24. Hooker A.C., Staatz C.E., Karlsson M.O. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007, 24:2187-2197.
25. Ribbing J., Niclas Jonsson E. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 2004, 31:109-134.
26. Aarons L., Rowland M., Balant L.P., Mentré F., Morselli P.L., Steimer J.L., et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996, 49:251-254.
27. Karlsson M.O., Savic R.M. Diagnosing model diagnostics. Clin Pharmacol Ther 2007, 82:17-20.
28. van der Meer A.F., Marcus M.A.E., Touw D.J., Proost J.H., Neef C. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 2011, 33:133-146.
29. Tjandramaga T.B., Van Hecken A., Mullie A., Verbesselt R., De Schepper P.J., Verbist L. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob Agents Chemother 1982, 22:237-241.
30. Neu H.C. The new beta-lactamase-stable cephalosporins. Ann Intern Med 1982, 97:408-419.
31. Tjandramaga T.B., Mullie A., Verbesselt R., De Schepper P.J., Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978, 14:829-837.
32. Van der Auwera P., Santella P.J. Pharmacokinetics of cefepime: a review. J Antimicrob Chemother 1993, 32(Suppl. B):103-115.
33. Moon Y.S., Chung K.C., Gill M.A. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 1997, 24(Suppl. 2):S249-S255.
34. Drusano G.L., Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl 1995, 96:11-16.
35. Mouton J.W., van den Anker J.N. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995, 28:275-286.
36. Jones T.E., Peter J.V., Field J. Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients. Anaesth Intensive Care 2009, 37:944-952.
37. Segal J.L., Gilman T.A., Thompson J.F. Single-dose gentamicin clearance is a predictor of creatinine clearance in spinal man. Am J Ther 2010, 17:390-395.
38. Zarowitz B.J., Robert S., Peterson E.L. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother 1992, 26:1205-1210.
39. Duffull S.B., Wright D.F.B., Winter H.R. Interpreting population pharmacokinetic-pharmacodynamic analyses-a clinical viewpoint. Br J Clin Pharmacol 2011, 71:807-814.